Pharmacy
Medical cost trends continue to plague the company as CVS says investors should no longer rely on previous guidance.
Total direct federal costs of covering AOMs would increase from $1.6 billion in 2026 to $7.1 billion in 2034, CBO finds.
The charges are unlawful distribution of about 70 million opioid pills and 30 million doses of other prescription drugs.
The lower price for members is due to a new Pharmacy Care Reimagined model that unbundles the traditional PBM model, company says.
Enrollees in high-need areas often lack access to providers who can prescribe or dispense these medications, OIG finds.
There is a shift from treating a disease to preventing it, says PhRMA chief medical officer Dr. Mike Ybarra.
Prices for 25 drugs are expected to decrease for Medicare beneficiaries starting in 2026 and continuing into 2027.
The drugmaker says it believes the rebate model is legally permissible and needed to improve the integrity of the 340B program.
The rebates paid by drug companies will be deposited into the Medicare Trust Fund.
The lower MA premiums are expected to drive enrollment to 35.7 million by 2025 - about 51% of all Medicare beneficiaries.